7.56
-0.16 (-2.07%)
| Previous Close | 7.72 |
| Open | 7.72 |
| Volume | 1,528,385 |
| Avg. Volume (3M) | 1,813,049 |
| Market Cap | 555,036,992 |
| Price / Sales | 1.80 |
| Price / Book | 1.12 |
| 52 Weeks Range | |
| Earnings Date | 28 Oct 2025 |
| Profit Margin | -10.92% |
| Operating Margin (TTM) | 37.82% |
| Diluted EPS (TTM) | -0.660 |
| Quarterly Revenue Growth (YOY) | 646.20% |
| Total Debt/Equity (MRQ) | 1.59% |
| Current Ratio (MRQ) | 4.58 |
| Operating Cash Flow (TTM) | -250.70 M |
| Levered Free Cash Flow (TTM) | -2.69 M |
| Return on Assets (TTM) | -5.39% |
| Return on Equity (TTM) | -7.34% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Arvinas, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 1.00 |
|
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 6.89% |
| % Held by Institutions | 90.98% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 18.00 (HC Wainwright & Co., 138.10%) | Buy |
| Median | 15.50 (105.03%) | |
| Low | 10.00 (BTIG, 32.28%) | Buy |
| Average | 14.83 (96.16%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 6.96 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 18 Sep 2025 | 10.00 (32.28%) | Buy | 7.72 |
| Stephens & Co. | 18 Sep 2025 | 14.00 (85.19%) | Buy | 7.72 |
| Barclays | 17 Sep 2025 | 16.00 (111.64%) | Buy | 7.61 |
| Guggenheim | 07 Aug 2025 | 15.00 (98.41%) | Buy | 6.24 |
| HC Wainwright & Co. | 07 Aug 2025 | 18.00 (138.10%) | Buy | 6.24 |
| Wells Fargo | 07 Aug 2025 | 16.00 (111.64%) | Buy | 6.24 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |